Emphysys, Inc.

Canaccord Genuity acts as Exclusive Financial Advisor to Emphysys, Inc. on its sale to Paramit Corporation, a portfolio company of Altaris Capital Partners

Canaccord Genuity is pleased to announce that on November 24, 2020, Emphysys, Inc. (“Emphysys” or “the Company”) was acquired by Paramit Corporation (“Paramit”), a portfolio company of Altaris Capital Partners (“Altaris”). Canaccord Genuity acted as the exclusive financial advisor to Emphysys.

Emphysys is an innovative engineering services company helping OEMs design next-generation technologies, with a concept-to-market approach from the earliest stages of applied research & technology development through prototyping & product development. The Company utilizes a systems-level approach that leverages deep domain expertise across multiple science, engineering and software disciplines to rapidly develop fundamental technology to help medical device, life science and industrial technology customers bring differentiated products to market more quickly.

Based in Silicon Valley with operations in the U.S., Europe, and Malaysia, Paramit develops and manufactures medical devices and life science instruments for its industry leading customers. Combined with Paramit's product design and manufacturing expertise, Emphysys will support the front end of the leading healthcare product realization solution that Paramit delivers for its customers. 

The Canaccord Genuity team consisted of Dan Coyne, Marc Marano, J.P. Michaud, Chris DiPietro, Scott Ahearn and Dan Grimes